Drug-Induced Injuries of the Liver and Biliary Tract

  • D. Larrey
Conference paper


Hepatic and biliary drug reactions have been increasingly recognized as major causes of liver and biliary tract diseases over the last 20 years [37, 66, 85, 90]. This may be explained by several factors. First, marked improvements have been made in diagnostic methods (viral serologic tests, ultrasonography, tomodensitometry, magnetic resonance imaging), allowing elimination of other causes of disease and ascertainment of potential involvement of drug reactions more accurately. Thus, the hepatotoxicity of some drugs, such as amiodarone or amodiaquin used for more than 25 years, was only recognized a few years ago [36, 70].


Acalculous Cholecystitis Tienilic Acid Granulomatous Hepatitis Liver Cell Necrosis Microvesicular Steatosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anderson SD, Nolley HC, Berland LL, Van Dyke JA, Stanley R (1986) Causes of jaundice during hepatic artery infusion chemotherapy. Radiology 161: 439–442PubMedGoogle Scholar
  2. 2.
    Anthony PP (1988) Liver tumours. Bailliere’s Clin Gastroenterol 2: 501–522CrossRefGoogle Scholar
  3. 3.
    Babany G, Uzzan F, Larrey D, Degott C, Bourgeois C, René E, Vissuzaine C, Erlinger S, Benhamou JP (1989) Alcoholic-like liver lesions induced by nifedipine. J Hepatol 9: 252–255PubMedCrossRefGoogle Scholar
  4. 4.
    Beaugrand M, Denis J, Callard P (1987) Tous les inhibiteurs calciques peuvent-ils entraîner des lésions d’hépatite alcoolique? Gastroenterol Clin Biol 10: 76Google Scholar
  5. 5.
    Beaune PH, Dansette PM, Mansuy D et al. (1987) Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Nat Acad Sci USA 84: 551–555PubMedCrossRefGoogle Scholar
  6. 6.
    Belghiti J, Benhamou JP, Houry S, Grenier P, Huguier M, Fekete F (1986) Caustic sclerosing cholangitis. A complication of the surgical treatment of hydatid disease of the liver. Arch Surg 121: 1162–1165PubMedCrossRefGoogle Scholar
  7. 7.
    Benichou C and an international group of experts (1990) Criteria of drug-induced liver disorders. J Hepatol 11: 272–276PubMedCrossRefGoogle Scholar
  8. 8.
    Biour M, Poupon R, Grange JD, Chazouilleres O, Levy VG, Bodin F, Cheymol G (1991) Hépatotoxicité des médicaments. Mise à jour du fichier bibliographique des atteintes hépatiques et des médicaments responsables. Gastroenterol Clin Biol 15: 64–78PubMedGoogle Scholar
  9. 9.
    Bjorge SM, Baillie TA (1985) Inhibition of medium-chain fatty acid ß-oxidation in vitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid. Biochem Biophys Res Com 132: 245–252PubMedCrossRefGoogle Scholar
  10. 10.
    Bourdi M, Larrey D, Nataf J, Bernuau J, Pessayre D, Iwasaki M, Guengerich FP, Beaune PH (1990) Anti-liver endoplasmic reticulum auto-antibodies are directed against human cytochrome P-450 IA2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest 85: 1967–1973PubMedCrossRefGoogle Scholar
  11. 11.
    Daudon M, Reveillaud RJ, Bigorie B (1988) Lithiase médicamenteuse du cholédoque. Presse Med 17: 869PubMedGoogle Scholar
  12. 12.
    Davion T, Capron JP (1991) Epidémiologie et facteurs de risque de la lithiase biliaire. In: Erlinger S, éd. La lithiase biliaire. Paris: Doin: 1–15Google Scholar
  13. 13.
    Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grange D, Machayekhi JP, Moreau A, Potet F, Benhamou JP (1992 Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 15: 244–251PubMedCrossRefGoogle Scholar
  14. 14.
    Degott C, Rueff B, Kreis H, Duboust A, Potet F, Benhamou JP (1978) Peliosis hepatis in recipients of renal transplants. Gut 19: 748–753PubMedCrossRefGoogle Scholar
  15. 15.
    De La Inglesia FA, Feuer G, Takada A, Matsuda Y (1974) Morphologic studies on secondary phospholipidosis in humans. Lab Invest 4: 539–549Google Scholar
  16. 16.
    Dikengil A, Siskind BN, Morse SS, Swedlund A, Bober-Sorcinelli KE, Burrel MI (1986) Sclerosing cholangitis from intra-arterial floxuridine. J Clin Gastroenterol 8: 690–693PubMedCrossRefGoogle Scholar
  17. 17.
    Dowling RH, Hussaini SH, Murphy GM, Besser GM, Wass JAH (1992) Gallstones during octreotide therapy. Metabolism 41: 22–33PubMedCrossRefGoogle Scholar
  18. 18.
    Dutertre JP, Bastides F, Jonville AP, De Muret A, Sonneville A, Larrey D, Autret E (1991) Microvesicular steatosis after ketoprofen administration. Eur J Gastroenterol Hepatol 3: 953–954Google Scholar
  19. 19.
    Eade OE, Grice D, Krawitt EL et al. (1981) HLA A and B locus antigens in patients with unexplained hepatitis following halothane anaesthesia. Tissue Antigens 17: 428–432PubMedCrossRefGoogle Scholar
  20. 20.
    Farrell G, Prendergast D, Murray M (1985) Halothane hepatitis. Detection of a constitutional susceptibility factor. N Engl J Med 313: 1310–1314PubMedCrossRefGoogle Scholar
  21. 21.
    Forbes GM, Jeffrey GP, Shilkin KB, Reed WD (1992) Carbamazepine hepato-toxicity: another cause of the vanishing bile duct syndrome. Gastroenterology 102: 1385–1388PubMedGoogle Scholar
  22. 22.
    Freneaux E, Larrey D, Pessayre D (1988) Stéatoses hépatiques médicamenteuses à triglycérides. Rev Fr Gastroenterol 240: 873–884Google Scholar
  23. 23.
    Geneve J, Hayat-Bonan B, Degott C, Letteron P, Freneaux E, Le Dinh T, Larrey D, Pessayre D (1987) Inhibition of mitochondrial β-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal antiinflammatory drug. J Pharmacol Exp Ther 242: 1133–1137PubMedGoogle Scholar
  24. 24.
    Heim-Duthoy KL, Caperton EM, Pollock R, Matzke GR, Enthoven D, Peterson PK (1990) Apparent biliary pseudolithiasis during ceftriaxone therapy. Anti-microb Agents Chemother 34: 1146–1149Google Scholar
  25. 25.
    Homberg JC, Abuaf N, Helmy-Khalil S, Biour M, Poupon R, Islam S, Darnis F, Levy VG, Opolon P, Beaugrand M, Toulet J, Danan G, Benhamou JP (1985) Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology 5: 722–727PubMedCrossRefGoogle Scholar
  26. 26.
    Horsmans Y, Lannes D, Pessayre D, Larrey D. (1991) Possible relationship between Atrium-induced hepatotoxicity and the genetic polymorphism in mephenytoin oxidation. Gastroenterology 100: A 828Google Scholar
  27. 27.
    Horsmans Y, Larrey D, Pessayre D, Benhamou JP (1990) Hépatotoxité des médicaments anti-infectieux. Première partie: Les antibiotiques antibactériens. Gastroenterol Clin Biol 14: 911–918PubMedGoogle Scholar
  28. 28.
    Ishak KG, Irey NS (1972) Hepatic injury associated with the phenothiazines. Clinico-pathologic and follow-up study of 36 patients. Arch Pathol 93: 283–304PubMedGoogle Scholar
  29. 29.
    Ishak KG, Zimmermann HJ (1987) Hepatotoxic effects of the anabolic-androgenic steroids. Semin Liver Dis 7: 230–236PubMedCrossRefGoogle Scholar
  30. 30.
    Ishak KG, Zimmermann HJ (1988) Drug-induced and toxic granulomatous hepatitis. Baillere’s clin gastroenterol 2: 463–480CrossRefGoogle Scholar
  31. 31.
    Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P (1987) Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 107: 459–465PubMedGoogle Scholar
  32. 32.
    Larrey D, Amouyal G, Danan G, Degott C, Pessayre D, Benhamou JP (1987) Prolonged cholestasis after troleandomycin-induced acute hepatitis. J Hepatol 4: 327–329PubMedCrossRefGoogle Scholar
  33. 33.
    Larrey D, Amouyal G, Pessayre D, Degott C, Danne O, Machayekhi JP, Feldmann G, Benhamou JP (1988) Amitriptyline-induced prolonged cholestasis. Gastroenterology 94: 200–203PubMedGoogle Scholar
  34. 34.
    Larrey D, Babany G, Bernuau J, Andrieux J, Degott C, Pessayre D, Benhamou JP. (1990) Fulminant hepatitis after lisinopril administration. Gastroenterology 99: 1832–1833PubMedGoogle Scholar
  35. 35.
    Larrey D, Berson A, Habersetzer F, Tinel M, Castot A, Babany G, Lettéron P, Freneaux E, Loeper J, Dansette P, Pessayre D (1989) Genetic predisposition to drug hepatotoxicity. Role in hepatitis caused by amineptine, a tricyclic antidepressant. Hepatology 10: 168–173PubMedCrossRefGoogle Scholar
  36. 36.
    Larrey D, Castot A, Pessayre D, Merigot P, Machayekhi JP, Feldmann G, Lenoir A, Rueff B, Benhamou JP (1986) Amodiaquine-induced hepatitis. A report of seven cases. Ann Intern Med 104: 801–803PubMedGoogle Scholar
  37. 37.
    Larrey D, Erlinger S (1988) Drug-induced cholestasis. Bailliere’s Clinical Gastroenterol 12:423–452CrossRefGoogle Scholar
  38. 38.
    Larrey D, Freneaux E, Berson A, Babany G, Degott C, Valla D, Pessayre D, Benhamou JP (1988) Peliosis hepatis induced by 6-thioguanine administration. Gut 29: 1265–1269PubMedCrossRefGoogle Scholar
  39. 39.
    Larrey D, Hadengue A, Pessayre D, Choudat L, Degott C, Benhamou JP (1987) Carbamazepine-induced acute cholangitis. Dig Dis Sci 32: 554–557PubMedCrossRefGoogle Scholar
  40. 40.
    Larrey D, Michel H (1993) Pathologie biliaire dûe aux médicaments. Gastroenterol clin biol (in press)Google Scholar
  41. 41.
    Larrey D, Pessayre D (1988) Genetic factors in hepatotoxicity. In: Liver cells and drugs. Ed Guillouzo A, Libbey J, London 164: 143–152Google Scholar
  42. 42.
    Larrey D, Pessayre D, Duhamel G, Casier A, Degott C, Feldmann G, Erlinger S, Benhamou JP (1986) Prolonged cholestasis after ajmaline-induced acute hepatitis. J Hepatol 2: 81–87PubMedCrossRefGoogle Scholar
  43. 43.
    Larrey D, Rueff B, Pessayre D, Danan G, Algard M, Geneve J, Benhamou JP (1986) Cross hepatotoxicity between tricyclic antidepressants. Gut 27: 726–727PubMedCrossRefGoogle Scholar
  44. 44.
    Larrey D, Vial T, Micaleff A, Babany G, Morichau-Beauchant M, Michel H, Benhamou JP (1992) Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut 33: 368–371PubMedCrossRefGoogle Scholar
  45. 45.
    Larrey D, Vial T, Pauwels A, Castot A, Biour M, David M, Michel H (1992) Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 117: 129–132PubMedGoogle Scholar
  46. 46.
    Levy M, Goodman M, Van Dyne BJ, Hatton S (1981) Granulomatous hepatitis secondary to carbamazepine. Ann Intern Med 95: 64–65PubMedGoogle Scholar
  47. 47.
    Lewis JH, Ranard RC, Caruso A, Jackson LK, Mullick F, Ishak KG, Seeff LB, Zimmermann HJ (1989) Amiodarone hepatotoxicity: prevalence and clinico-pathologic correlations among 104 patients. Hepatology 9: 679–685PubMedCrossRefGoogle Scholar
  48. 48.
    Loeper J, Descatoire V, Amouyal G, Lettéron P, Larrey D, Pessayre D (1989) Presence of covalently bound metabolites on rat hepatocyte plasma membrane proteins after administration of isaxonine, a drug leading to immunoallergic hepatitis in man. Hepatology 9: 675–678PubMedCrossRefGoogle Scholar
  49. 49.
    Loeper J, Descatoire V, Maurice M, Beaune P, Feldmann G, Larrey D, Pessayre D (1990) Presence of functional cytochrome P-450 on isolated rat hepatocyte plasma membrane. Hepatology 11: 850–858PubMedCrossRefGoogle Scholar
  50. 50.
    Ludwig J, Kim CH, Wiesner RH, Krom RAF (1989) Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? Hepatology 9: 215–218PubMedCrossRefGoogle Scholar
  51. 51.
    Lüllmann H, Lüllmann-Rauch R, Wassermann O (1975) Drug-induced phospho-lipidoses. CRC Critical Rev Toxicol 4: 185–242Google Scholar
  52. 52.
    Makuuchi M, Sukigara M, Mori T, Kobayashi J, Yamazaki S, Hasegawa H (1985) Bile duct necrosis: compilation of transcatheter hepatic arterial embolization. Radiology 156: 331–334PubMedGoogle Scholar
  53. 53.
    McKnight JA, McCance DR, Atkinson AB, Crothers JG (1989) Changes in glucose tolerance and development of gallstones during high dose treatment with octreotide for acromegaly. Br Med J 299: 1162–1163CrossRefGoogle Scholar
  54. 54.
    McMaster KR, Hennigar GG (1981) Drug-induced granulomatous hepatitis. Lab Invest 44: 61–73PubMedGoogle Scholar
  55. 55.
    Meyer WJ, Wiener I, Emory LE, Cole CM, Isenberg N, Fagan CJ et al. (1992) Cholelithiasis associated with medroxyprogesterone acetate therapy in men. Res Comm Chem Pathol Pharmacol 75: 69–84Google Scholar
  56. 56.
    Miguet JP, Vuitton D, Allemand H et al. (1980) Une épidémie d’ictères dus à l’association troléandomycine-contraceptifs oraux. Gastroenterol Clin Biol 4: 420–424PubMedGoogle Scholar
  57. 57.
    Moesch C, Gainant A, Sautereau D (1988) Lithiase biliaire de glafénine. Identification par spectrophotométrie infrarouge. Gastroenterol Clin Biol 12: 387–389PubMedGoogle Scholar
  58. 58.
    Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S (1984) Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1057–1064Google Scholar
  59. 59.
    Neiderhiser DH (1986) Acute acalculous cholecystitis induced by lysophosphati-dylcholine. Am J Pathol 124: 559–563PubMedGoogle Scholar
  60. 60.
    Neuberger, J, Forman D, Doll R, Williams R (1986) Oral contraceptives and hepatocellular carcinoma. Br Med J 292: 1355–1357CrossRefGoogle Scholar
  61. 61.
    Pagliaro L, Campesi G, Aguglia F (1969) Barbiturate jaundice. Report of a case due to a barbital-containing drug, with positive rechallenge to phenobarbital. Gastroenterology 56: 938–943PubMedGoogle Scholar
  62. 62.
    Paquette P, Campos LT, Flax I, McElmurry S, Dossey JE, Miro-Quesada M (1987) Prevention and treatment of sclerosing cholangitis related to chemotherapy delivered by infusaid pump. Proc Am Soc Clin Oncol 6: 89Google Scholar
  63. 63.
    Pariente A, Hamoud A, Goldfain et al. (1989) Hépatites à la clométacine (Dupé-ran). Etude rétrospective de 30 cas. Un modèle d’hépatite immunoallergique. Gastroenterol Clin Biol 13: 769–774PubMedGoogle Scholar
  64. 64.
    Parry SW, Pelias ME, Browder W (1988) Acalculous hypersensitivity cholecystitis: hypothesis of a new clincopathologic entity. Surgery 104: 911–916PubMedGoogle Scholar
  65. 65.
    Pessayre D, Bichara M, Feldmann G, Degott C, Potet F, Benhamou JP (1979) Perhexiline maleate-induced cirrhosis. Gastroenterology 76: 170–177PubMedGoogle Scholar
  66. 66.
    Pessayre D, Larrey D (1988) Acute and chronic drug-induced hepatitis. Baillere’s Clin Gastroenterol 2: 385–422CrossRefGoogle Scholar
  67. 67.
    Pessayre D, Larrey D (1988) Mechanisms of drug-induced hepatitis. In: Liver Cells and Drugs. Ed. Guillouzo A, Libbey J London 164: 129–142Google Scholar
  68. 68.
    Pessayre D, Larrey D, Funck-Bretano D, Benhamou JP (1985) Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 16 (suppl A): 181–194PubMedGoogle Scholar
  69. 69.
    Pitre J, Houssin D, Louvel A, Vigouroux C, Gaudric M, Chapuis Y (1991) Cho-langite ectasiante et cirrhose biliaire secondaire après chimiothérapie intra-artérielle hépatique. Gastroenterol Clin Biol 15: 350–354PubMedGoogle Scholar
  70. 70.
    Poucell S, Ireton J, Valencia-Mayoral P, Downar E, Larratt L, Patterson J, Blen-dis L, Phillips J (1984) Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology 86: 926–936PubMedGoogle Scholar
  71. 71.
    Prescott LF (1983) Paracetamol overdosage. Pharmacological considerations and clinical management. Drugs 25: 290–314PubMedCrossRefGoogle Scholar
  72. 72.
    Prigrau C, Pahissa A, Gropper S, Sureda D, Martínez-Vásquez JM (1989) Ceftriaxone-associated biliary pseudolithiasis in adults. Lancet 1: 165CrossRefGoogle Scholar
  73. 73.
    Review by an International Group (1983) Histopathology of the intrahepatic biliary tract. Liver 3: 161–175Google Scholar
  74. 74.
    Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Hill AP, Tyler CW (1979) The cooperative liver tumor study group — epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 242: 645–648CrossRefGoogle Scholar
  75. 75.
    Rougier P (1986) Chimiothérapie intra-artérielle hépatique des métastases isolées des adénocarcinomes colo-rectaux. Gastroenterol Clin Biol 10: 122–130PubMedGoogle Scholar
  76. 76.
    Schaad UB, Wedgwood-Krucko J, Tschaeppeler H (1988) Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet 2: 1411–1413PubMedCrossRefGoogle Scholar
  77. 77.
    Seeff LB, Cuccherini BA, Zimmerman HJ, Adler EA, Benjamin SB (1986) Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. Ann Intern Med 104: 399–404PubMedGoogle Scholar
  78. 78.
    Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W (1986) Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 105: 179–183PubMedGoogle Scholar
  79. 79.
    Simon JB, Manley PN, Brien JF, Armstrong PW (1984) Amiodarone hepatotoxi-city simulating alcoholic liver disease. N Engl J Med 311: 167–172PubMedCrossRefGoogle Scholar
  80. 80.
    Spes CH, Angermann CE, Beyer RW, Schreiner J, Lehnert P (1990) Increased incidence of cholelithiasis in heart transplant recipients receiving cyclosporin therapy. Transplantation 9: 404–407Google Scholar
  81. 81.
    Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Herlong HF (1981) Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 305: 722–727PubMedCrossRefGoogle Scholar
  82. 82.
    Steiner A, Weisser B, Vetter WA (1991) A comparative review of the adverse effects of treatments for hyperlipidaemia. Drug Saftety 6: 118–130CrossRefGoogle Scholar
  83. 83.
    Stolzer B, Miller G, White WA, Zuckerbrod M (1950) Postarsenical obstructive jaundice complicated by xanthomatosis and diabetes mellitus. Am J Med 9: 124–132PubMedCrossRefGoogle Scholar
  84. 84.
    Stricker BHCH, Block R, Claas FHJ, Parys GEV, Desmet VJ (1988) Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 8: 599–606PubMedCrossRefGoogle Scholar
  85. 85.
    Stricker BHCH, Spoelstra P (1985) Drug-induced hepatic injury. A comprehensive survey of the literature on adverse drug reactions up to January 1985 ; Elsevier, Amsterdam 1985Google Scholar
  86. 86.
    Valla D, Benhamou JP (1988) Liver diseases related to oral contraceptives. Dig Dis 6: 76–86PubMedCrossRefGoogle Scholar
  87. 87.
    Valla D, Benhamou JP (1988) Drug-induced vascular and sinusoidal lesions of the liver. Baillere’s Clin Gastroenterol 2: 481–500CrossRefGoogle Scholar
  88. 88.
    Yeung E, Jackson J, Finn JP, Thomas MG, Benjamin IS, Adam A (1990) Acal-culous cholecystis complicating hepatic intraarterial Lipiodol: case report. Cardi-ovasc Intervent Radiol 12: 80–82CrossRefGoogle Scholar
  89. 89.
    Zafrani ES, Pinaudeau Y, Dhumeaux D (1983) Drug-induced vascular lesions of the liver. Arch Intern Med 143: 495–802PubMedCrossRefGoogle Scholar
  90. 90.
    Zimmerman HJ (1978) Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. Appleton-Century-Crofts, New York 1978Google Scholar
  91. 91.
    Zimmerman HJ, Lewis JH (1987) Drug-induced cholestasis. Med Toxicol 2: 112–160PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • D. Larrey
    • 1
  1. 1.Service d’Hépato-gastroentérologieHôpital Saint-EloiMontpellierFrance

Personalised recommendations